ClinicalTrials.gg
RecruitingNCT07680803Updated Jul 27, 2026

Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia

A Phase 2 interventional study of FT007 in Transfusion-dependent Beta-Thalassemia, sponsored by Fondazione Telethon. Recruiting at 2 sites in Italy. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Fondazione Telethon · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
3 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in beta-Thalassemia with a site in Italy — 8 open to participants now, 17 under way, 6 of them phase 3. beta-Thalassemia · Italy.

Planned enrollment
38th of 39
9 · median 55
Started
2026
the only one that year
Phase 2
18 of 49
2 open now
Primary completion
2028-10
later than 14 of 16 live
Registered
49th of 49
by date

Among the 49 studies in beta-Thalassemia with a site in Italy, this one is the 38th largest by planned enrollment of the 39 interventional ones that give a count, is the only one that started in 2026, is one of 18 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 49th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

8 of the 49 studies in beta-Thalassemia with a site in Italy are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 3 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in beta-Thalassemia with a site in Italy, or all of them as a file.
02

Study summary

This is a prospective, dual-centre, single dose, Phase IIb, single arm, open label study. The proposed clinical trial involves a single infusion of autologous HSPCs genetically modified with the GLOBE lentiviral vector, using an improved transduction protocol in 9 patients affected by transfusion dependent Beta-Thalassemia.

Four study phases are foreseen:

  1. Screening phase, during which the conditions required by the clinical protocol for patients' inclusion/exclusion will be assessed after the signature of the informed consents/assents. Patients will be recruited from the two participating sites: IRCCS Ospedale San Raffaele (OSR), Department of Pediatric Immunohematology and adult Hematology (OSR Stem Cells Programme) (Milan) and IRCCS Ospedale Pediatrico Bambino Gesù (OPBG), Department of Haematology, Oncology and Gene and Cell Therapy (Rome).
  2. Baseline phase, carried from the end of the screening phase to the day before the start of the conditioning regimen.
  3. Treatment phase, from the first day of conditioning regimen until DP administration.
  4. Follow-up phase: from DP administration until 2 years follow-up.
03

Conditions studied

  • Transfusion-dependent Beta-Thalassemia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be willing to adhere to the protocol as evidenced by written for adults or parental informed consent and subject assent for adolescents and children.
  2. Male and female adults/adolescents/children diagnosed with transfusion-dependent β-thalassemia (homozygous or compound heterozygous). At least 2 out of the 9 patients must have B0/B0 or B0/B0-like genotype. In case the genetic diagnosis available at screening wasn't performed in a certified laboratory (check under PI's or delegated investigator's responsibility), the genetic diagnosis will be repeated at clinical sites during the screening phase.
  3. Documented history of at least 100 ml/kg/year or 10 U/year of packed red blood cell transfusions in each of the 2 years prior to signing informed consent.
  4. Age ≥ 18 years and ≤ 35 years for Group 1, Age ≥ 3 years and ≤ 35 years for Group 2.
  5. Index or Lansky ≥ 80%.
  6. Adequate cardiac, renal, hepatic and pulmonary functions resulting in eligibility to undergo HSCT as evidenced by:

    1. (LVEF) greater than 45% by echo and normal or presence of abnormalities not significant for cardiac disease. Absence of severe pulmonary hypertension.
    2. Diffusing capacity of the lung for carbon monoxide (DLCO) > 50% and in 1 sec (FEV1) and forced expiratory vital capacity (FVC) > 60% predicted (if non cooperative: pulse oximetry > 95 % in room air).
    3. Serum creatinine \< 2 x and estimated > 60 ml/min/1.73m2, calculated using the CKD-EPI formula (Levey 2009) for adults and the modified Schwartz formula (Schwartz 2009) for pediatric patients.
    4. Absent-mild-moderate liver iron overload on T2*MRI (i.e. LIC \< 15 mg Fe/gr dry weight assessed at screening. T2*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment centers).
    5. Absent-mild-moderate cardiac iron overload T2*MRI (i.e. > 20 msec assessed at screening. T2*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment centers).
    6. Absence of severe liver fibrosis or cirrhosis on Shear Wave (less than 6 months before enrolment) or of other advanced liver disorder.
  7. For all patients in reproductive age, agreement to use highly effective and adequate method of for at least 12 months following DP administration (including both females of and males with partners of childbearing potential).
  8. Good adherence to transfusion and chelation programme, as indirect evidence of good adherence to treatment and follow-up evaluations for the current trial.
  9. Availability of an adequate and well documented transfusion history (at least previous 24 months) or availability to follow a regular transfusion regimen according to guidelines and provide a detailed transfusion record of the 24 months prior to the DP administration.

Exclusion criteria

Exclusion Criteria:

  1. Use of other agents within 4 weeks prior to study enrolment (within 6 weeks if use of long-acting agents).
  2. Severe, active viral, bacterial or fungal infection at eligibility evaluation.
  3. Current or prior malignant neoplasia (except local skin cancer or cervical intraepithelial neoplasia) or exceptional family history of familial cancer syndromes.
  4. Current or prior immunodeficiency disorder.
  5. History of uncontrolled seizures.
  6. (AST), alanine transaminase (ALT) >3 × the (ULN), or direct value >2.5 × ULN.
  7. Baseline (International Normalized Ratio; INR) >1.5 × ULN.
  8. Other clinical conditions judged non compatible with the procedure and/or the treatment.
  9. Positivity for (serology or RNA), and/or HbsAg and/or and/or (patients who have completed antiviral treatment for HCV may only be enrolled if they have achieved a sustained virologic response, defined as undetectable HCV RNA at least 12 weeks after completion of therapy) and/or evidence of active infection of Treponema Pallidum or Mycoplasma species.
  10. Positive history of significant previous thrombotic events. In case of a positive thrombophilic screening, patient's inclusion will be evaluated according to national guidelines.
  11. Active alcohol or substance abuse within 6 months of the study.
  12. Pregnancy or lactation.
  13. Previous hematopoietic stem cell transplantation.
  14. Previous gene therapy treatment (gene addition or gene editing).
  15. For patients until the age of 14 years only: availability of an HLA-matched family donor.
  16. Patients with associated α-thalassemia and >1 alpha deletion, or alpha multiplications.
  17. Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    subjects with transfusion-dependent beta-thalassemia

    Genetic: FT007

Interventions

  • GeneticFT007

    Autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with the lentiviral vector GLOBE encoding for the human beta globin using an improved transduction protocol, re-suspended in their final formulation medium and cryopreserved.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who achieve TI12 in the 2 years from DP administration

    Proportion of Subjects achieving transfusion independence defined as a weighted average Hb ≥ 9.0 gr/dL without any red blood cell transfusion for a continuous period of ≥ 12 months (TI12) at any time during the study after the drug product administration The assessment of TI12 starts 60 days after last RBC transfusion for post-transplant support or BTHAL standard of care.

    Time frame: from 60 days after the IMP infusion, to 24 months of follow-up

Secondary outcomes

  1. Overall survival

    Overall survival at 12 and 24 months post IMP infusion

    Time frame: 12 months and 24 months post IMP infusion

  2. Proportion of Subjects who achieve hematological engraftment ≤ day +60 from DP administration

    Proportion of Subjects who achieve hematological engraftment ≤ day +60 from DP administration defined as first day of absolute neutrophil count ≥ 0.5 x 10\^9/L on 3 consecutive measurements obtained on different days and platelets ≥20x 10\^9/L in the absence of platelet transfusions and/or growth factor support for at least 7 consecutive days.

    Time frame: from Day 11 to Day 60 post IMP infusion

  3. Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) (Safety and tolerability of the administration of FT007)

    Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) attributed to procedures related to harvesting of HSPCs, conditioning regimen, FT007 administration (from screening to 24 months post GT).

    Time frame: from Baseline to 24 months post IMP infusion

  4. Proportion of Subjects with abnormal clonal proliferation development due to insertional mutagenesis

    Proportion of Subjects with abnormal clonal proliferation development due to insertional mutagenesis

    Time frame: 6, 12, 18 and 24 months post IMP infusion

  5. Polyclonal and multilineage engraftment evaluated by VCN and ISA

    ISA will be carried out at 3, 6, 12, 18, 24 months on total nucleated cells and different hematopoietic lineages (granulocytes, lymphocytes, erythroid cells) from PB and/or BM. The criteria to assess "polyclonality" of hematopoiesis is defined as \> 1000 unique integration sites retrieved at 3, 6, 12, 18 and 24 months after gene therapy from PB and/or BM cells when available. Clonal dominance will be assessed from 3 months after GT and will be defined as the presence of a vector integration that constitutes \> 30% with respect to the total integrations retrieved from whole peripheral blood cells in at least 3 consecutive timepoints and with an increase in the relative contribution over time. Vector-specific quantitative PCR will be performed on PB and/or BM erythroid cells at screening, 1, 2, 3, 6, 12,18 and 24 months after GT (at 1 and 18 months only on PB, at 24 months after GT. Adequate engraftment is defined as ≥ 0.8 VCN/genome on BM erythroid cells and CD15+ cells.

    Time frame: screening, 1, 2, 3, 6, 12, 18 and 24 months after IMP infusion

  6. Proportion of Subjects with immune reconstitution

    Proportion of Subjects with immune reconstitution defined as CD4+ \>200 at 6 and 12 months post GT. Immune-monitoring will be evaluated at baseline and at follow-up time points (6 and 12 months of follow-up). The frequency and functionality of lymphoid compartment (B, T, NK cells) in PB and BM, including humoral and cellular responses will be evaluated.

    Time frame: 6 and 12 months post IMP infusion

  7. Characterization of Subjects achieving TI12

    Duration of TI12 and the time from IMP infusion to last RBC transfusion prior to becoming TI12 will be evaluated. Weighted average Hb during TI12 and the proportion of subjects who meet the definition of TI12 at 24 months will be also evaluated.

    Time frame: 24 months after IMP infusion

  8. Characterization of transfusion reduction (TR) among subjects not achieving TI12

    Percentage of treated subjects with a reduction in the ml/kg RBC transfused from Month 12 through Month 24 (a 12-month period) after DP infusion of at least 50%, 60%, 75%, 90% or 100% compared to the average annual ml/kg RBC transfusion requirement during the 2 years prior to enrolment will be recorded. Moreover, the number of transfusions from Month 12 through Month 24 compared to the average number of annual transfusions during the 2 years prior to enrolment will be collected and analyzed. Two years of retrospective pre-transplant data will be collected for each subject in the study, so that each subject may serve as his/her own control for the parameters of RBC transfusion requirements.

    Time frame: 12 and 24 months post IMP infusion

  9. Health-related quality of life (HRQoL) - PedsQL

    HRQoL will be assessed by the use of standardized questionnaires: PedsQL quality of life version 4.0 up to 25 years of age, according to patient's age. PedsQL quality of life will be assessed at 12 and 24 months of follow-up compared to baseline.

    Time frame: baseline, 12 and 24 months

  10. Health-related quality of life (HRQoL) - FACT BMT

    HRQoL will be assessed by the use of standardized questionnaires: FACT BMT version 4 for adults. FACT BMT will be assessed at 12 and 24 months of follow-up compared to baseline.

    Time frame: baseline, 12 and 24 months

  11. Health-related quality of life (HRQoL) - EQ-5D-5L

    HRQoL will be assessed by the use of standardized questionnaires: EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) for adults

    Time frame: baseline, 12 and 24 months

  12. Health-related quality of life (HRQoL) - EQ-5D-Y

    HRQoL will be assessed by the use of standardized questionnaires: EuroQol Quality of Life Scale-5 dimensions-5 levels of severity the EuroQol Quality of Life Scale-5 dimensions youth (EQ-5D-Y) for children and adolescents.

    Time frame: baseline, 12 and 24 months

  13. Proportion of Subjects with engraftment of genetically corrected cells

    Proportion of Subjects with engraftment of genetically corrected cells (expressed as VCN ≥ 0.8 on bone marrow erythroid cells and CD15+ cells). Engraftment will be assessed by vector-specific quantitative PCR on bone marrow erythroid cells at 6, 12, and 24 months after IMP infusion.

    Time frame: 6, 12, and 24 months after IMP infusion

  14. Levels of biomarkers indicative of ineffective erythropoiesis before and after gene therapy at different time points.

    Evaluation of plasma iron level, erythropoietin (EPO), soluble serum transferrin receptor (sTfR), Lactate Dehydrogenase (LDH) and Bilirubin will be evaluated as surrogate of ineffective erythropoiesis at screening and 1, 3, 6, 12, 24 months. Decreased levels of these parameters correlate with ineffective erythropoiesis improvement.

    Time frame: screening and 1, 3, 6, 12, 24 months after IMP infusion

  15. Shear Wave Elastography and Liver Iron Concentration (LIC) over time

    Shear Wave Elastography and LIC will be performed at screening and at 12, 24 months after infusion of DP (T2\*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment sites); in selected cases liver biopsy can be performed.

    Time frame: screening, 12 and 24 months after IMP infusion

  16. Cardiac T2* value over time

    Cardiac T2\* value will be assessed through T2\*MRI at screening and at 12, 24 months after infusion of DP (T2\*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment sites).

    Time frame: screening, 12 and 24 months after IMP infusion

  17. Ferritin serum levels over time

    Serum ferritin will be evaluated at screening, 3, 6, 12, 18, 24 months after infusion of DP.

    Time frame: screening, 3, 6, 12, 18 and 24 months after IMP infusion

  18. Proportion of patients free from any iron-chelating therapy, including regular phlebotomies at month 24

    The proportion of patients free from iron-chelation therapy, including regular phlebotomies in the entire cohort will be evaluated at month 24 after infusion of DP.

    Time frame: 24 months after IMP infusion

  19. Duration of iron-chelating treatment after DP infusion

    The duration of iron chelation therapy following DP infusion will be assessed. This includes the time from DP infusion to the last documented administration of iron chelation treatment.

    Time frame: from Day 1 to 24 months post IMP infusion

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2028, 27 months after the start.

Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 2, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2030
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07680803
Lead sponsor
Fondazione Telethon
Collaborators
Ospedale San Raffaele
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Jul 6, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2030 (estimated)
Last update
Jul 27, 2026

Study contacts

Alessandro Aiuti, Professor
Contact
aiuti.alessandro@hsr.it
+39 02 26439057

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion